Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4132 | vadadustat Wiki | 1.00 |
drug272 | Apremilast placebo Wiki | 1.00 |
drug1800 | Lanadelumab placebo Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Description: Confirmed clinical recovery means the participant is fit for discharge from hospital. Fit for discharge is defined by achieving a score of 6, 7, or 8 on the 8-point ordinal scale of clinical severity status, without being re-hospitalized prior to Day 29. 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Time to confirmed clinical recovery Time: Baseline (Day 1) to Day 29Description: Oxygen-free recovery is defined as participants who are alive, discharged, and not receiving supplement oxygen
Measure: Number of participants who achieve oxygen-free recovery at Day 29 Time: Day 29Description: Fit for discharge is defined by achieving a score of 6, 7, or 8 on the 8-point ordinal scale of clinical severity status, without being re-hospitalized prior to Day 29. 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who experience ≥2-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29 Time: Baseline (Day 1) to Day 29Description: All-cause mortality is death due to any cause.
Measure: Incidence of all-cause mortality Time: Baseline (Day 1) to Day 29Description: 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29 Time: Day 8, Day 15 and Day 29Description: 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Worst post-baseline score on the 8-point ordinal scale of clinical severity status Time: Baseline (Day 1) to Day 29Description: Clinical recovery is defined by achieving a score of 6, 7 or 8 on the 8-point ordinal scale of clinical severity status. 8-point ordinal scale of clinical severity status scores are Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29 Time: Day 8, Day 15, and Day 29Description: Sustained clinical recovery is defined by achieving a score of 6, 7 or 8 on the 8-point ordinal scale of clinical severity status at follow-up visit (Day 60). 8-point ordinal scale of clinical severity status scores are Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who achieve sustained clinical recovery at Day 60 Time: Day 60Description: An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A TEAE is an AE that occurs after the use of study treatment.
Measure: Number of participants who experience one or more treatment-emergent adverse events (TEAEs) Time: Baseline (Day 1) to End of Study (Day 60)Description: An SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability or incapacity, is a congenital anomaly or birth defect, or is considered to be serious by the Investigator.
Measure: Number of participants who experience one or more serious adverse events (SAEs) Time: Baseline (Day 1) to End of Study (Day 60)Description: The CTCAE defines grade 3 and above as: Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden). Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Measure: Number of participants who experience one or more common terminology criteria for adverse events (CTCAE) grade 3 or higher Time: Baseline (Day 1) to End of Study (Day 60)Description: An adverse event (AE) leading to dose modification is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment that leads to a change in dose of study treatment.
Measure: Number of participants who experience one or more adverse events (AEs) leading to dose modification Time: Baseline (Day 1) to End of Study (Day 60)Description: An adverse event (AE) leading to discontinuation is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment that leads to the participant discontinuing the study.
Measure: Number of participants who experience one or more adverse events (AEs) leading to discontinuation Time: Baseline (Day 1) to End of Study (Day 60)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports